Prohibitin 3′ Untranslated Region Polymorphism and Breast Cancer Risk

AACR logo

DOI: Published November 2003

Article Figures & Data

Table 1

Prohibitin 3′ UTR C/T polymorphism genotype distribution among cases and controls

Group	CC			CT			TT
Group		N (%)	P value^a	N (%)	P value^a (OR, 95% CI)	N (%)	P value^a (OR, 95% CI)	N (%)	P value^a (OR, 95% CI)
Controls	170 (71.4)		61 (25.6)		7 (3.0)		68 (28.6)
All breast cancer	188 (64.6)	1.00	93 (32.0)	0.1 (1.3, 0.9–2.0)	10 (3.4)	0.6 (1.3, 0.5–3.5)	103 (35.4)	0.1 (1.3, 0.9–2.0)
Under 40 BrCa^b	142 (68.3)	1.00	59 (28.4)	0.5 (1.2, 0.7–1.7)	7 (3.3)	0.8 (1.2, 0.4–3.5)	66 (31.7)	0.5 (1.2, 0.7–1.7)
Familial^c BrCa	123 (64.1)	1.00	65 (33.8)	0.1 (1.5, 0.9–2.2)	4 (2.1)	0.7 (0.7, 0.2–2.8)	69 (35.9)	0.1 (1.4, 0.9–2.1)

a Fisher’s exact test (two-sided) for the relevant genotype using the CC genotype as reference. The ORs and 95% CIs are shown in brackets.
b BrCa, breast cancer.
c Family history is defined as two or more cases of breast cancer reported in first or second degree female relatives or bilateral breast cancer.